Clinical trials: PDA
Ductus Arteriosus, Patent
NIT-OCCLUD PDA Phase II Sentinel Trial
The purpose of this study is to evaluate the safety and efficacy of the Nit-Occlud -PDA Occlusion System for transcatheter closure of PDA with minimum angiographic diameter less than 4 mm, and to compare one year safety and…
- Trial name
- NCT00828334
- Testing
- Transcatheter PDA Coil
- Where
- 15 sites in United States
- Volunteers
- 357 people
- Sponsor
- PFM Medical, Inc
Patent Ductus Arteriosus
Assessment of Therapeutic Effect of Rectal Vs. Intravenous Paracetamol in The Treatment of Patent Ductus Arteriosus (PDA) in Neonates
To compare the effectiveness of rectal vs. intravenous paracetamol in the medical treatment of significant PDA in neonates.
- Trial name
- NCT06256211
- Testing
- Paracetamol
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Soha mahmoud Hussien mahdy
Patent Ductus Arteriosus
Safety and Efficacy Study of Ibuprofen l-Lysine Solution in Premature Infants for Treatment of PDA
The purpose of this study is to determine the safety and effectiveness of ibuprofen l-lysine iv in premature infants in the early treatment of Patent Ductus Arteriosus.
- Trial name
- NCT00440804
- Testing
- ibuprofen l-lysine iv solution (NeoProfen (R) )
- Sponsor
- Farmacon
Patent Ductus Arteriosus in Preterm Infants
Radiological Markers for PDA Management in Preterm Infants
The aim of this Randomized controlled trial is to determine whether Echo with Organ Doppler-guided management strategy for hemodynamically significant patent ductus arteriosus (hsPDA) improves the short-term outcomes compared…
- Trial name
- NCT07812064
- Testing
- Organ doppler, Echocardiography
- Volunteers
- 88 people
- Sponsor
- Assiut University
Infant, Premature, Congenital Heart Disease
Splanchnic and Renal Tissue Oxygenation During Enteral Feedings in Neonates With Patent Ductus Arteriosus
Patent ductus arteriosus (PDA) is a common problem in the neonatal intensive care unit and can be secondary to prematurity or congenital heart disease (CHD).
- Conditions
- Infant, Premature, Congenital Heart Disease, Patent Ductus Arteriosus, Necrotizing Enterocolitis
- Trial name
- NCT03551600
- Testing
- Near-infrared spectroscopy (NIRS)
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- University of Utah
Patent Ductus Arteriosus
Near Infrared Spectroscopy to Determine Patent Ductus Arteriosus Closure
Using cerebral and renal near infrared spectroscopy monitoring to determine PDA closure in preterm infants after completing medical treatment for a hemodynamically significant PDA.
- Trial name
- NCT03026192
- Testing
- near infrared spectroscopy
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Albany Medical College
Patent Ductus Arteriosus
Treating the Resistant Patent Ductus Arteriosus (PDA)
Persistent postnatal ductal patency may have significant adverse hemodynamic effects, frequently necessitating therapeutic intervention in order to facilitate ductal closure.
- Trial name
- NCT00616382
- Testing
- Indomethacin, Pentoxifylline
- Where
- Israel
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Shaare Zedek Medical Center
Patent Ductus Arteriosus
Efficacy and Safety of Oral Versus Intravenous Ibuprofen for PDA Treatment in ELBW Infants
To determine whether oral or intravenous ibuprofen has a better or same efficacy and tolerance in closure of patent ductus arteriosis in extremely-low-birth-weight preterm infants.
- Trial name
- NCT01261117
- Testing
- oral ibuprofen
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Zekai Tahir Burak Women's Health Research and Education Hospital
Patent Ductus Arteriosus
Safety and Effectiveness Study With a New PDA Occluder for Closure of Patent Ductus Arteriosus
The objective of the study is to investigate the safety, efficacy and clinical utility of the Occlutech PDA device for closure of patent ductus arteriosus of all types.
- Trial name
- NCT01479218
- Testing
- Occlutech PDA occluder
- Where
- 2 sites in Malaysia, Vietnam
- Volunteers
- 50 people
- Sponsor
- Occlutech International AB
Patent Ductus Arteriosus, Extreme Prematurity
Canadian National PDA Treatment Study
Patent ductus arteriosus (PDA) is the most common cardiovascular problem that develops in preterm infants. Persistent PDA may result in higher rates of death, chronic lung disease (CLD), pulmonary hemorrhage, necrotizing…
- Trial name
- CANRxPDA (NCT04347720)
- Testing
- Indomethacin, Ibuprofen, Acetaminophen
- Where
- 22 sites in Canada
- Volunteers
- 1,663 people
- Sponsor
- IWK Health Centre
Locally Advanced Pancreatic Ductal Adenocarcinoma (PDA)
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.
- Trial name
- NCT06984562
- Testing
- Adaptive Radiation Therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Fox Chase Cancer Center
Bronchopulmonary Dysplasia, Patent Ductus Arteriosus
MISA to NRDS：a Multicenter Study in China
BACKGROUND Treatment of neonatal respiratory distress syndrome with exogenous surfactant and mechanical ventilation made millions of preterm infants survived in neonatal intensive care unit (NICU).
- Conditions
- Bronchopulmonary Dysplasia, Patent Ductus Arteriosus, Intraventricular Hemorrhage, Necrotizing Enterocolitis
- Trial name
- NCT04077333
- Testing
- Minimal Invasive surfactant administration
- Where
- China
- Volunteers
- 237 people
- Sponsor
- Peking University Third Hospital
Ductus Arteriosus, Patent, Preterm Infants
New Management Strategy of PDA for VLBW Preterm Infants
Patent ductus arteriosus (PDA) is one of the most common complications in premature infants. Successful pharmacological closure of PDA with indomethacin was first reported in 1976.
- Trial name
- NCT00239512
- Testing
- Indomethacin and Ibuprofen
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- China Medical University Hospital
Patent Ductus Arteriosus
Paracetamol Treatment of the Borderline Significant PDA
The therapeutic approach to the patent ductus arteriosus (PDA) in the premature neonate remains controversial. Currently it is generally accepted to treat only hemodynamically significant PDAs.
- Trial name
- NCT02819414
- Testing
- Paracetamol drops
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Shaare Zedek Medical Center
Depression, Pregnancy
Patient Decision Aid for Antidepressant Use in Pregnancy
The proposed study is a pilot randomized controlled trial (RCT) of an electronic patient decision aid (PDA) for antidepressant use in pregnancy.
- Trial name
- NCT02492009
- Testing
- Standard Resource Sheet, Patient Decision Aid
- Where
- United Kingdom
- Volunteers
- 51 people
- Sponsor
- King's College London
Patent Ductus Arteriosus, Neonate
Combination of Acetaminophen and Ibuprofen in the Management of Patent Ductus Arteriosus
Patent ductus arteriosus or PDA is a blood vessel that connects the right and left side of the heart that usually closes after birth but remains open in some premature infants born before 30 weeks' gestation.
- Trial name
- NCT03103022
- Testing
- Acetaminophen, ibuprofen
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Patent Ductus Arteriosus, Preterm Infant
Randomized Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus
The purpose of the present study is to determine whether treatment of hemodynamically significant patent ductus arteriosus with a combined therapy of intravenous Ibuprofen and oral acetaminophen has higher success rate in closing…
- Conditions
- Patent Ductus Arteriosus, Preterm Infant, Bronchopulmonary Dysplasia
- Trial name
- NCT03701074
- Testing
- Ibuprofen and acetaminophen
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of South Alabama
Infant, Premature, Ductus Arteriosus, Patent
Urine NT-proBNP Levels and Echocardiographic Findings in Very Low Birth Weight (VLBW) Infants
The aim of the study is to evaluate urine NT-proBNP levels and new Echocardiographic Findings in VLBW infants. The investigators hypothesize that high urine NT-proBNP concentrations are associated with a hemodynamically…
- Conditions
- Infant, Premature, Ductus Arteriosus, Patent, Ventricular Function, Left
- Trial name
- NCT00799123
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Charite University, Berlin, Germany
Relapsing-Remitting Multiple Sclerosis
Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)
Aim of the BETAPATH study is to evaluate whether the use of a personal digital assistant (PDA) can improve the adherence of Multiple Sclerosis patients to a therapy with Betaseron.
- Trial name
- NCT00902135
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- Germany
- Volunteers
- 702 people
- Sponsor
- Bayer
Patent Ductus Arteriosus, Patent Ductus Arteriosus - Delayed Closure
Timing of Surgical PDA Ligation and Neonatal Outcomes
Patent ductus arteriosus (PDA) is common among very preterm infants. If pharmacological closure is ineffective or contraindicated, surgical ligation may be required.
- Conditions
- Patent Ductus Arteriosus, Patent Ductus Arteriosus - Delayed Closure, Patent Ductus Arteriosus After Premature Birth
- Trial name
- NCT04126512
- Testing
- PDA ligation
- Where
- 2 sites in Italy, United Kingdom
- Volunteers
- 78 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna